Chiron Rejects Novartis’ Offer
This article was originally published in The Gray Sheet
Executive Summary
Chiron's board of directors has rejected Novartis' Aug. 31 offer to buy the remaining 58% of Chiron, the firm announced Sept. 5. Novartis' offer of $4.5 bil. ($40.00 per share) is "inadequate," according to Chiron's board. Chiron's stock jumped 18% from $36.44 on Aug. 31 to $42.93 on Sept. 1 and closed $42.79 on Sept. 5. Novartis bought 42% of Chiron in 1995. "Over the 10 years since Novartis has been Chiron's largest stockholder, Chiron has regularly discussed with Novartis a number of strategic initiatives," Chiron states in a release. "As a result, Chiron has had an on-going dialogue with Novartis regarding its intentions with respect to its investment in Chiron. The firm's independent directors have not, however, solicited an offer to buy Chiron." Chiron manufactures blood-testing products, including the Procleix nucleic acid testing system (1"The Gray Sheet" Sept. 5, 2005, In Brief)...
You may also be interested in...
Novartis buys Chiron
Novartis enters definitive agreement with Chiron Oct. 31 to buy the remaining 58% of the company for $45 a share, or about $5.1 bil. in cash. The deal is subject to approval of Chiron's shareholders, other than Novartis, and is expected to close in early 2006. In August, Chiron's board of directors rejected a buyout offer from Novartis of $40 per share ($4.5 bil.) (1"The Gray Sheet" Sept. 12, 2005, In Brief). On Nov. 3, Novartis announced its intention to appoint its current Global Head of Pharma Development Joerg Reinhardt, PhD, to head-up the new diagnostics and vaccines division that will be created from Chiron business units...
Chiron correction
Gen-Probe manufacturers the Procleix nucleic acid testing system, while Chiron distributes Gen-Probe's blood screening assays. "The Gray Sheet" mistakenly reported that Chiron manufacturers Procleix (1"The Gray Sheet" Sept. 12, 2005, p. 2)...
Novartis seeks Chiron buy
Novartis offers Chiron $4.5 bil. in cash for the remaining 57.8% of the company, both companies announce Aug. 31. Novartis purchased a 42.2% stake in the firm in 1995. Blood-testing products, including the firm's flagship Procleix nucleic acid testing system, accounted for $494.1 mil. of Chiron's $1.7 bil. revenue in 2004. The rest is from vaccines ($479 mil.) and biopharmaceuticals ($563 mil.). Novartis said it will seek a customary merger agreement with the independent directors of Chiron's board, but notes that the acquisition is subject to approval by a majority of the Chiron shares not owned by the Swiss firm...